Four Step Asymmetric Synthesis of the Anti-asthma Drug Singulair

Summary

 

Technology Description

 

This technology is a simple and efficient way for synthesizing Singulair, a drug for the treatment of asthma and sesonal allergies.

 

Features & Benefits

 

  • Much more efficient and quicker synthesis pathway than that being used by big pharama (Merck)

 

Applications

 

  • Treatment for asthma and other allergic symptoms

 

Background of Invention

 

FDA approved commercial medication for asthma and other allergic symptoms features Singulair. The drug is currently manufactured by a Merck process that requires 10 steps and proceeds in 6.8% overall yield. Researchers at Oregon State University have discovered a very efficient way of synthesizing Singulair. This drug could have powerful implications for treatment of depression and neuropathic pain. Our synthesis requires 4 steps, proceeds in 73.3% overall yield and uses a novel catalyst we designed and developed for the key step­introduction of the important sulfur constituent into the molecule.

 

 

 

Patent Information:
Tech ID:
OSU-14-42
Contact:
Jianbo Hu
IP & Licensing Manager
Oregon State University
541-737-2366
Jianbo.Hu@oregonstate.edu
Inventors:
James White
Subrata Shaw
Keywords:
© 2017. All Rights Reserved. Powered by Inteum